Call Our Invokana Lawsuit Attorneys for Compassionate Counsel
If you took or are taking any of a class of diabetes medications called SGLT2 inhibitors and have experienced serious side effects, Crumley Roberts may be able to help. Our firm represents patients who have experienced serious injuries or complications after taking Invokana®, Invokamet®, Farxiga®, and other SGLT2 inhibitor diabetes medications. Leg and foot amputations, ketoacidosis, and other medical problems have been associated with these diabetes drugs.
Our Firm Is Here For You
We at Crumley Roberts are committed to protecting the rights of the injured. Although it may seem difficult or impossible to create a brighter future after experiencing serious diabetes drug side effects, our team can offer a shoulder to lean on and experienced counsel to seek compensation for your medical treatment, ongoing medical care, lost earnings, and possibly more.
We are currently investigating drug injury lawsuits related to:
- Invokana® (canagliflozin)
- Invokamet® and Invokamet XR® (canagliflozin and metformin)
- Farxiga® (dapagliflozin)
- Xigduo XR® (dapagliflozin and metformin extended-release)
- Jardiance® (empagliflozin)
- Glyxambi® (empagliflozin and linagliptin)
Amputation Risk & Ketoacidosis Associated with SGLT2 Inhibitor Diabetes Drugs
SGLT2 inhibitors have been associated with severe side effects. The Food and Drug Administration (FDA) has issued safety communications regarding their link to an increased amputation risk and ketoacidosis.
- In May of 2015, the FDA reported that patients who take SGLT2 inhibitors may develop ketoacidosis, a condition that occurs when there is a lack of insulin in the body, leading to a potentially fatal acid buildup. Symptoms may include nausea, vomiting, abdominal pain, difficulty breathing, and tiredness. SGLT2 inhibitors were also linked to kidney infections, blood infections, and urinary tract infections.
- According to a May 2017 FDA Drug Safety Communication, canagliflozin (marketed as Invokamet®, Invokana®, and Invokamet XR®) is associated with an increased risk of toe, foot, or leg amputations. The FDA required manufacturers to place Boxed Warnings on canagliflozin products.